**S4 Table.** Post-hoc analysis with an additional criterion for drug use in the overall population, requiring a prescription of ≥30 days within 6 months before the coronavirus disease testing

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug** | **Controls(N=59,977)** | **Cases(N=5,172)** | **Crude** | **Adjusted** |
| **OR** **(95% CI)** | **P** | **OR** **(95% CI)** | **P** |
| **Drugs with potential therapeutic effects** |
| Hydroxychloroquine | 77 (0.13) | 4 (0.08) | 0.61 (0.22–1.65) | 0.326 | 0.92 (0.32–2.60) | 0.868 |
| Camostat | 45 (0.08) | 1 (0.02) | 0.26 (0.04–1.87) | 0.181 | 0.65 (0.09–4.82) | 0.674 |
| Statins | 3,686 (6.15) | 243 (4.70) | 0.75 (0.66–0.86) | <0.001 | 1.02 (0.86–1.21) | 0.829 |
| Mycophenolate | 82 (0.14) | 5 (0.10) | 0.71 (0.29–1.75) | 0.453 | 1.22 (0.48–3.10) | 0.684 |
| Amiodarone | 98 (0.16) | 0 (0.00) |  | 0.901 |  | 0.900 |
| **Drugs with concerns regarding increased risk** |
| Angiotensin receptor blockers | 3,296 (5.50) | 229 (4.43) | 0.80 (0.70–0.91) | 0.001 | 1.15 (0.97–1.37) | 0.098 |
| Angiotensin-converting enzyme inhibitors | 148 (0.25) | 13 (0.25) | 1.02 (0.58–1.80) | 0.949 | 1.50 (0.83–2.70) | 0.178 |
| Metformin | 1,338 (2.23) | 76 (1.47) | 0.65 (0.52–0.83) | <0.001 | 0.90 (0.69–1.16) | 0.408 |
| Thiazolidinedione | 211 (0.35) | 15 (0.29) | 0.82 (0.49–1.39) | 0.469 | 1.12 (0.65–1.93) | 0.696 |
| **Drugs with no expected benefits** |
| NSAIDs | 2,444 (4.07) | 174 (3.36) | 0.82 (0.70–0.96) | 0.013 | 0.98 (0.83–1.17) | 0.848 |
| COX2 inhibitors | 689 (1.15) | 44 (0.85) | 0.74 (0.54–1.00) | 0.053 | 1.03 (0.74–1.42) | 0.861 |
| Aspirin | 60 (0.10) | 2 (0.04) | 0.39 (0.10–1.58) | 0.186 | 0.93 (0.22–3.89) | 0.920 |
| Systemic steroids | 1,287 (2.15) | 50 (0.97) | 0.45 (0.34–0.59) | <0.001 | 0.63 (0.46–0.86) | 0.003 |
| Proton pump inhibitors | 2,973 (4.96) | 159 (3.07) | 0.61 (0.52–0.72) | <0.001 | 0.87 (0.72–1.05) | 0.150 |
| N-acetylcysteine | 785 (1.31) | 34 (0.66) | 0.50 (0.35–0.70) | <0.001 | 0.88 (0.62–1.27) | 0.500 |